OncoCyte Corporation (AMEX:OCX) will look for acquisitions. On January 2, 2020 OncoCyte entered into Subscription Agreements (the "Subscription Agreements") with selected investors, including largest shareholder Broadwood Partners, L.P. The sale of the shares of common stock is expected to close during the week of January 6, 2020, subject to the satisfaction of customary closing conditions. OncoCyte may use net proceeds to invest in or acquire businesses or technologies that are complementary to business, although have no binding agreements with respect to any acquisitions, other than previously disclosed agreements to acquire Razor Genomics.